Your browser doesn't support javascript.
Glucocorticoid Therapy in COVID-19.
Amati, Francesco; Tonutti, Antonio; Huston, John; Dela Cruz, Charles S.
  • Amati F; Respiratory Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Tonutti A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Huston J; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Dela Cruz CS; Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Critical Care and Sleep Medicine, Center for Pulmonary Infection Research and Treatment, Yale School of Medicine, New Haven, Connecticut.
Semin Respir Crit Care Med ; 44(1): 100-117, 2023 02.
Article in English | MEDLINE | ID: covidwho-2227451
ABSTRACT
Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic proportions. Inflammation in response to the infection contributes to the pathogenesis of pneumonia. This review will discuss prior studies on the use of glucocorticoids to treat respiratory infections, the rationale for the use glucocorticoids in COVID-19, and review of existing data. We will also highlight outstanding research questions for future studies.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Journal: Semin Respir Crit Care Med Journal subject: Critical Care Year: 2023 Document Type: Article Affiliation country: S-0042-1759778

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Journal: Semin Respir Crit Care Med Journal subject: Critical Care Year: 2023 Document Type: Article Affiliation country: S-0042-1759778